Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / HIMS
Stock rating · Services-Offices & Clinics of Doctors of Medicine
Hims & Hers Health, Inc. (HIMS) Stock Rating & Analysis
As of October 12, 2026, MELANY rates Hims & Hers Health, Inc. 51 out of 100 (Promising). Its highest factor score is price momentum at 81, and its lowest are business quality and risk-adjusted profile at 25.
MELANY ratingRated 2026-10-12HIMS · composite score
About Hims & Hers Health, Inc.
Hims & Hers, launched in 2017, is a telehealth platform connecting patients with healthcare providers for specialties such as erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. With more than 2 million subscribers, it operates in all 50 states and some European markets such as the UK.
Rating as of 2026-10-12 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why HIMS scores 51/100
HIMS's 8 factor scores run from 25 to 81, and 2 of them sit above its composite of 51. Here is how HIMS breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- FCF yield 11.8%
Margins, returns on capital, and balance-sheet strength.
- Gross margin 72%
Direction and relative strength of the recent share-price trend.
- Price +4.9% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How HIMS compares
As of October 13, 2026, Hims & Hers Health, Inc. ranks 20th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 65.
Key risks for HIMS
- High debt-to-equity ratio 4.8x, rate-sensitive balance sheet
- Operating margin -13%, cash-burn business, dependent on capital markets
- Short interest 28% of float, high volatility risk on news
- High beta 2.4, amplifies market drawdowns 1.8x+ in selloffs
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Hims & Hers Health, Inc. sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 69/100 for strength. Theme strength feeds HIMS's momentum and catalyst factors above.
HIMS trade plan (Pro)
MELANY has a full position plan for Hims & Hers Health, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates HIMS
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Hims & Hers Health, Inc.'s 51/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about HIMS
Is Hims & Hers Health, Inc. (HIMS) a buy?
As of 2026-10-12, MELANY rated Hims & Hers Health, Inc. Promising with a composite score of 51/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Hims & Hers Health, Inc.'s MELANY score?
Hims & Hers Health, Inc. (HIMS) has a MELANY composite score of 51/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the HIMS stock rating calculated?
MELANY scores HIMS from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Hims & Hers Health, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Hims & Hers Health, Inc. (HIMS) Promising with a composite of 51/100 as of 2026-10-12. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the HIMS stock price forecast?
MELANY does not publish price targets or forecasts for HIMS. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 51/100 across eight factors for Hims & Hers Health, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is HIMS stock overvalued or undervalued?
MELANY's valuation factor currently reads 45/100 for Hims & Hers Health, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives HIMS's read.
What price should I buy HIMS at?
Rather than chasing the current price, MELANY computes a smart entry zone for HIMS: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying HIMS stock?
The top risks MELANY currently flags for Hims & Hers Health, Inc.: High debt-to-equity ratio 4.8x, rate-sensitive balance sheet; Operating margin -13%, cash-burn business, dependent on capital markets; Short interest 28% of float, high volatility risk on news; High beta 2.4, amplifies market drawdowns 1.8x+ in selloffs; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Hims & Hers Health, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 25/100 for Hims & Hers Health, Inc., and earnings track record, at 31/100. The 51/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will HIMS stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 81/100 for HIMS right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this HIMS rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-12. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores HIMS continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, HIMS included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.